Literature DB >> 18066551

Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis.

Paolo Airo'1, Mirko Scarsi, Mara Rossi, Michele Mondini.   

Abstract

The coexistence of systemic sclerosis (SSc) and multiple sclerosis (MS) in the same patient has been described in few cases. We refer here a further case of association between these diseases, which highlight the difficulty of treating such patients. A 57-year-old male with relapsing-remitting MS since 20 years, shortly after having received high-dose corticosteroids for a relapse of MS, suddenly developed SSc, with onset of Raynaud phenomenon simultaneous to that of scleroderma skin involvement, new appearance of accelerated arterial hypertension, and rapidly progressive oliguric renal failure, indicative of scleroderma renal crisis, that was controlled with ramipril, irbesartan and amlodipin. A further disabling relapse of MS was treated with interferon-beta, but 19 months later he developed multiple severe digital necrotic ulcers, that resolved with interferon discontinuation and therapy with iloprost. This case report shows that some form of treatment useful for MS might enhance the manifestations of SSc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18066551     DOI: 10.1007/s00296-007-0507-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  The 77C->G mutation in the human CD45 (PTPRC) gene leads to increased intensity of TCR signaling in T cell lines from healthy individuals and patients with multiple sclerosis.

Authors:  Hue-Tran Do; Wiebke Baars; Katja Borns; Anja Windhagen; Reinhard Schwinzer
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

2.  Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group.

Authors:  P Airò; M Rossi; M Scarsi; E Danieli; A Grottolo; A Zambruni
Journal:  Clin Exp Rheumatol       Date:  2007 Sep-Oct       Impact factor: 4.473

3.  Systemic sclerosis (scleroderma) and multiple sclerosis.

Authors:  D C Trostle; D Helfrich; T A Medsger
Journal:  Arthritis Rheum       Date:  1986-01

4.  Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.

Authors:  Paul J DeMarco; Michael H Weisman; James R Seibold; Daniel E Furst; Weng Kee Wong; Eric L Hurwitz; Maureen Mayes; Barbara White; Fredrick Wigley; Walter Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Philip J Clements
Journal:  Arthritis Rheum       Date:  2002-11

5.  [Severe Raynaud's phenomenon associated with interferon-beta therapy for multiple sclerosis: case report].

Authors:  B A Cruz; E D Queiroz; S V Nunes; A Cruz Filho; G B Campos; E L Monteiro; H Crivellari
Journal:  Arq Neuropsiquiatr       Date:  2000-06       Impact factor: 1.420

6.  A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.

Authors:  Michele Mondini; Matteo Vidali; Marco De Andrea; Barbara Azzimonti; Paolo Airò; Roberta D'Ambrosio; Piersandro Riboldi; Pier Luigi Meroni; Emanuele Albano; Yehuda Shoenfeld; Marisa Gariglio; Santo Landolfo
Journal:  Arthritis Rheum       Date:  2006-12

7.  Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis.

Authors:  R Solans; J A Bosch; I Esteban; M Vilardell
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

Review 8.  Demyelination in rheumatic diseases.

Authors:  A Theodoridou; L Settas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

9.  Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C.

Authors:  Hiroki Tahara; Akira Kojima; Tomoyuki Hirokawa; Tatsuya Oyama; Atsushi Naganuma; Sakae Maruta; Katsuyuki Okada; Satoshi Ban; Katsue Yoshida; Hitoshi Takagi; Masatomo Mori
Journal:  Intern Med       Date:  2007-04-17       Impact factor: 1.271

10.  Multiple sclerosis associated with systemic sclerosis.

Authors:  Syngliti-Henrietta Pelidou; Niki Tsifetaki; Sotiris Giannopoulos; Georgia Deretzi; Paraskevi Voulgari; Athanassios Kyritsis
Journal:  Rheumatol Int       Date:  2006-12-14       Impact factor: 3.580

View more
  3 in total

1.  Prevalence of ocular manifestations in systemic sclerosis patients.

Authors:  Arleta Waszczykowska; Roman Goś; Elżbieta Waszczykowska; Bożena Dziankowska-Bartkowiak; Piotr Jurowski
Journal:  Arch Med Sci       Date:  2013-11-29       Impact factor: 3.318

2.  Follow-up of hypertension in patients with multiple sclerosis.

Authors:  Seyed Mohammad Baghbanian
Journal:  Iran J Neurol       Date:  2016-07-06

3.  Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity.

Authors:  Dimitris K Karathanasis; Anna Rapti; Adrianos Nezos; Charalampos Skarlis; Constantinos Kilidireas; Clio P Mavragani; Maria Eleftheria Evangelopoulos
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.